PMID- 16313321
OWN - NLM
STAT- MEDLINE
DCOM- 20060131
LR  - 20131121
IS  - 0902-0063 (Print)
IS  - 0902-0063 (Linking)
VI  - 19
IP  - 6
DP  - 2005 Dec
TI  - Predictors of health-related quality of life in hypertensive recipients following 
      renal transplantation.
PG  - 756-62
AB  - BACKGROUND: Health-related quality of life (HRQoL) improves after renal 
      transplantation. However, it is unclear which variables are the strongest 
      determinants of HRQoL following renal transplantation. In this study, we wanted 
      to assess whether antihypertensive medication, donor type, human leukocyte 
      antigen (HLA)-compatibility or other variables could predict HRQoL 6-12 months 
      after transplantation. METHODS: The study was a follow up of 124 patients 
      recruited to a single center, randomized, double-blind clinical trial, comparing 
      the effects of lisinopril and nifedipine in hypertensive renal transplant 
      recipients. HRQoL was assessed with the Short Form 36 (SF-36) questionnaire. 
      Bivariate and multiple linear regression analysis were used to assess the 
      relationship between potential predictors and the physical component summary 
      (PCS) and mental component summary (MCS) scales of the SF-36. RESULTS: Average 
      scores 6-12 months after transplantation did not differ between patients 
      randomized to lisinopril or nifedipine, or between cadaveric and living donor 
      recipients on any of the eight SF-36 scales, or the two summary scales. In 
      multivariate analyses, recipient age (p = 0.01) and cold ischemia time >14.5 h (p 
      = 0.04) were independent predictors of the PCS score. Recipient age (p = 0.05), 
      2-4 HLA-AB mismatches (p = 0.05) and donor age (p = 0.03) were independent 
      predictors of the MCS score. CONCLUSIONS: There was no evidence of differences in 
      HRQoL according to lisinopril or nifedipine, or living vs. cadaveric donor 
      transplantation. HRQoL was significantly reduced with longer cold ischemia time 
      and more than one HLA-AB mismatches, after adjusting for age. These donor kidneys 
      related issues need confirmation.
FAU - Aasebo, Willy
AU  - Aasebo W
AD  - Medical Department, Akershus University Hospital, Nordbyhagen, Norway. 
      waaseboe@online.no
FAU - Midtvedt, Karsten
AU  - Midtvedt K
FAU - Hartmann, Anders
AU  - Hartmann A
FAU - Stavem, Knut
AU  - Stavem K
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Calcium Channel Blockers)
RN  - E7199S1YWR (Lisinopril)
RN  - I9ZF7L6G2L (Nifedipine)
SB  - IM
MH  - Adult
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Calcium Channel Blockers/*therapeutic use
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Hypertension/drug therapy/*etiology
MH  - Kidney Transplantation/*adverse effects
MH  - Linear Models
MH  - Lisinopril/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nifedipine/therapeutic use
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
EDAT- 2005/11/30 09:00
MHDA- 2006/02/01 09:00
CRDT- 2005/11/30 09:00
PHST- 2005/11/30 09:00 [pubmed]
PHST- 2006/02/01 09:00 [medline]
PHST- 2005/11/30 09:00 [entrez]
AID - CTR416 [pii]
AID - 10.1111/j.1399-0012.2005.00416.x [doi]
PST - ppublish
SO  - Clin Transplant. 2005 Dec;19(6):756-62. doi: 10.1111/j.1399-0012.2005.00416.x.